COMMUNIQUÉS West-GlobeNewswire

Q BioMed and Mannin Research to Develop GDF15 Biomarker Glaucoma Diagnostic Kit Through Collaboration with McMaster University
19/03/2019
Enabling technology to more effectively manage glaucoma progression and patient treatment Serves unmet need - Currently no single examination or diagnostic test is able to accurately predict disease progression Simple [...]
Altimmune Announces Positive Results from NasoVAX Extension Study
19/03/2019
Seroprotective HAI antibody response persisted more than one year after vaccination Company seeking partnership for further development and commercialization of NasoVAX GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE [...]
VBL Presents New Data on Potential of VB-111 to Stimulate the Immune System and Drive Immune Cells to Infiltrate Tumor Microenvironment
19/03/2019
Data Presented at Society of Gynecologic Oncology (SGO) 50th Annual Meeting on Women's Cancer® TEL AVIV, Israel, March 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announced the presentation of [...]
Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax
19/03/2019
GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and safety of AV7909 ( [...]
Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology’s 68th Annual Scientific Session
19/03/2019
Anti-Oxidant Effects of Eicosapentaenoic Acid Data at Pharmacologic Concentrations Also Presented BEDMINSTER, N.J., and DUBLIN, Ireland, March 19, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a [...]
Amphastar Pharmaceuticals Receives FDA Approval for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial
19/03/2019
RANCHO CUCAMONGA, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (FDA) granted approval of its Abbreviated New Drug [...]
Affimed Announces Milestone Payment from Genentech and ROCK® Platform Presentation at Innate Killer Summit 2019, Further Highlighting Leadership in Innate Immunity
19/03/2019
Heidelberg, Germany, March 19, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that the Company [...]
Innovate Biopharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 19, 2019
19/03/2019
Investor conference call at 8AM ET and earnings press release scheduled for before the market opens on March 19, 2019 RALEIGH, N.C., March 18, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) ( [...]
Immutep to Present IMP761 Preclinical Results in Global Webcast
19/03/2019
SYDNEY, Australia, March 18, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune [...]
Auxly to Report 2018 Financial Results on March 29, 2019
18/03/2019
VANCOUVER, British Columbia, March 18, 2019 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V - XLY) (" Auxly " or the " Company ") today announced that it plans to report its fourth quarter and full fiscal year 2018 [...]
CORRECTION - IntelGenx to Report Fourth Quarter and Full-Year 2018 Financial Results on March 22, 2019 – Conference Call to Follow on March 25, 2019
18/03/2019
SAINT LAURENT, Quebec, March 18, 2019 (GLOBE NEWSWIRE) -- In a release issued under a similar headline earlier today by IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT), please note that the financial results [...]
Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress
18/03/2019
Initiated and Progressed Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers, Transitioning to a Clinical-Stage Company Presented Compelling Preclinical Data from the SRK-181 Cancer Immunotherapy Program at the [...]
RavenQuest Completes Non-Brokered Private Placement
18/03/2019
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS VANCOUVER, British Columbia, March [...]
aTyr Pharma to Announce Fourth Quarter and Full Year 2018 Financial Results on March 25th
18/03/2019
Company to host conference call and webcast at 5pm EDT / 2pm PDT SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of [...]
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
18/03/2019
On track to initiate Phase 3 VITAL™ trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house Manufacturing scaled to support AAV based programs; GMP readiness expected 2H19 Investor conference call on [...]
Dermira Announces Proposed Public Offering of Common Stock
18/03/2019
MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies [...]
Syneos Health Reports Fourth Quarter and Full Year 2018 Results
18/03/2019
Highlights GAAP total revenue of $1.15 billion and $4.39 billion for the fourth quarter and year ended December 31, 2018, respectively. Adjusted service revenue under ASC 606 of $1.15 billion and $4.40 billion for the [...]
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
18/03/2019
CORAL GABLES, Fla., March 18, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with [...]
resTORbio, Inc. Announces Proposed Public Offering of Common Stock
18/03/2019
BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. ("resTORbio" or the "Company") (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to [...]

Pages